PFF Patient Communication Center: The destination for latest disease education information

The newly launched Pulmonary Fibrosis Foundation Patient Communication Center (PCC) has become the destination for the most up-to-date information for the pulmonary fibrosis community. The PCC now has information about the Expanded Access Program (EAP) for pirfenidone.

"The Pulmonary Fibrosis Foundation (PFF) is committed to serve as an impartial resource for the PF community," said Patti Tuomey, EdD, President and Chief Operating Officer. "The PFF is enthusiastic about the changing landscape of available treatments for this devastating and fatal disease. We are pleased to be able to share all the latest information with the community." 

Today, InterMune, Inc. announced that the company will provide compassionate use of pirfenidone through a multi-center Expanded Access Program (EAP) in the United States. There are a limited number of participating sites accepting patients at this time, but it is expected that all clinical sites will be ready to accept patients by the end of September.

"Patients and caregivers have been waiting for the development of new IPF treatments. An Expanded Access Program allows patients to actively participate in the search for therapies that may positively impact their health," said Gregory Cosgrove, MD, Chief Medical Officer for the Pulmonary Fibrosis Foundation. "The PFF welcomes all medical news concerning the development of potential treatments and is committed to sharing these updates with the PF community." Dr. Cosgrove is Associate Professor of Medicine in the Pulmonary Division at National Jewish Health in Denver, CO.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Can loneliness lead to diabetes? New study reveals the role of physical activity and BMI